Render Target: SSR
Render Timestamp: 2024-12-19T20:45:26.103Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-20 06:22:15.623
Product last modified at: 2024-09-20T07:06:12.661Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

CD45RA (HI100) Mouse mAb (APC-Cy7® Conjugate) #37674

Filter:
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa)
    Source/Isotype Mouse IgG2b kappa
    Application Key:
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Description

    This Cell Signaling Technology antibody is conjugated to APC-Cy7® and tested in-house for direct flow cytometric analysis in human cells.

    Product Usage Information

    Application Dilution
    Flow Cytometry (Live) 1:20

    Storage

    Supplied in 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH 7.2. This product is stable for 6 months when stored at 4ºC. Do not aliquot the antibody. Protect from light. Do not freeze.

    Protocol

    Specificity / Sensitivity

    CD45RA (HI100) Mouse mAb (APC-Cy7® Conjugate) recognizes endogenous levels of total CD45RA protein. This antibody detects an epitope within the extracellular domain.

    Species Reactivity:

    Human

    Source / Purification

    This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.

    Background

    The protein phosphatase (PTP) receptor CD45 is a type I transmembrane protein comprised of a pair of intracellular tyrosine phosphatase domains and a variable extracellular domain generated by alternative splicing (1). The catalytic activity of CD45 is a function of the first phosphatase domain (D1) while the second phosphatase domain (D2) may interact with and stabilize the first domain, or recruit/bind substrates (2,3). CD45 interacts directly with antigen receptor complex proteins or activates Src family kinases involved in the regulation of T- and B-cell antigen receptor signaling (1). Specifically, CD45 dephosphorylates Src-family kinases Lck and Fyn at their conserved negative regulatory carboxy-terminal tyrosine residues and upregulates kinase activity. Conversely, studies indicate that CD45 can also inhibit Lck and Fyn by dephosphorylating their positive regulatory autophosphorylation site. CD45 appears to be both a positive and a negative regulator that conducts signals depending on specific stimuli and cell type (1). Human leukocytes including lymphocytes, eosinophils, monocytes, basophils, and neutrophils express CD45, while erythrocytes and platelets are negative for CD45 expression (4).
    Several isoforms of CD45 are generated through alternative splicing in a cell type-specific and activation state-specific manner. The HI100 antibody is widely used as a leukocyte marker for naïve and activated T cells. Naïve T cells are positive for CD45RA, where activated T cells are negative for CD45RA (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    Cy and CyDye are registered trademarks of GE Healthcare.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.